Trial details
FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)
To find out more about this trial and your cancer treatment options, please speak with your doctor.
Trial short name: HPVDNA02
Official title: FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)
Principal Investigator: Dr. Eric Leung
Cancer type: Gynecology
Cancer location: Cervix
Disease stage: Early and Advanced Cancer
Trial phase: Other
Intervention: Diagnostic Test: [18-F]-FDG - PET
Registration #:
NCT03853915 
Trial description:
PATIENT ENROLLMENT FOR THIS TRIAL IS CURRENTLY ON HOLD DUE TO COVID-19 RESTRICTIONS
Nearly all cervical cancers are caused by the human papilloma virus (HPV), which can be detected in cancer tissue by laboratory tests. There is evidence that the virus can also be detected from a blood sample to monitor the effects of treatment. Previous studies have shown that a special test called 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET-CT) at 3 months after treatment may predict survival in cervical cancer patients.
The purpose of this study is to see how well the FDG-PET Scan and blood tests for HPV can detect leftover cervical cancer cells after treatment. This study is not a particular form of treatment and patients will receive standard of care treatment.
Inclusion Criteria: • Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IB-IVA • Planned for radical radiotherapy and concurrent cisplatin chemotherapy. • Age ≥ 18 years. Exclusion Criteria: • Evidence of distant metastases (suspicious paraaortic nodes below the renal vessels allowed if they will be encompassed within the radiation field) • Patients who have received any anticancer treatment for their cervical cancer. • Other cervical cancer tumor histologies (e.g. small cell, serous) • Contraindications to 18FDG PET-CT • Contraindication to radiotherapy (e.g. severe Crohn's disease) • Contraindication to chemotherapy (e.g. non-reversible renal failure) • History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ years. • Known pregnancy or lactating
